| scholarly article | Q13442814 |
| P50 | author | Gabriel Liberale | Q39519575 |
| P2093 | author name string | D Elias | |
| B Raynard | |||
| T Matsuhisa | |||
| M Pocard | |||
| M Ducreux | |||
| P Bourget | |||
| V Billard | |||
| J M Puizillou | |||
| L Drouard-Troalen | |||
| L Sideris | |||
| P433 | issue | 10 | |
| P921 | main subject | oxaliplatin | Q422327 |
| peritoneal carcinomatosis | Q2071182 | ||
| pharmacokinetics | Q323936 | ||
| irinotecan | Q412197 | ||
| P304 | page(s) | 1558-1565 | |
| P577 | publication date | 2004-10-01 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance | |
| P478 | volume | 15 |
| Q34580450 | A prospective multicenter phase II study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trial |
| Q34996489 | Activity ex vivo of cytotoxic drugs in patient samples of peritoneal carcinomatosis with special focus on colorectal cancer |
| Q83498250 | Appraisal of peritoneal cavity's capacity in order to assess the pharmacology of liquid chemotherapy solution in hyperthermic intraperitoneal chemotherapy |
| Q34605976 | Body surface area predicts plasma oxaliplatin and pharmacokinetic advantage in hyperthermic intraoperative intraperitoneal chemotherapy |
| Q85059510 | Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis |
| Q37308725 | Clinical practice guidelines for the management of metastatic colorectal cancer: a consensus statement of the Hellenic Society of Medical Oncologists (HeSMO). |
| Q33394590 | Closed abdomen hyperthermic intraperitoneal chemotherapy with irinotecan and mitomycin C: a phase I study |
| Q50868425 | Complications and toxicities after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. |
| Q39964992 | Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin Increases the Risk of Postoperative Hemorrhagic Complications: Analysis of Predictive Factors. |
| Q38112342 | Cytoreductive surgery and intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis from colorectal origin |
| Q38183786 | Drug development for intraperitoneal chemotherapy against peritoneal carcinomatosis from gastrointestinal cancer |
| Q53058208 | Effects of Oxaliplatin Treatment on the Myenteric Plexus Innervation and Glia in the Murine Distal Colon |
| Q48680971 | HPLC analysis and extraction method of SN-38 in brain tumor model after injected by polymeric drug delivery system |
| Q91749747 | Hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis: a clinical pharmacological perspective on a surgical procedure |
| Q42924756 | Impact of the hyperthermic intraperitoneal chemotherapy on the fluid-electrolytes changes and on the acid-base balance |
| Q52362144 | Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics. |
| Q41715552 | Linear Relationship of Peritoneal Cancer Index and Survival in Patients with Peritoneal Metastases from Colorectal Cancer |
| Q46827170 | Malignant peritoneal mesothelioma: treatment with maximal cytoreductive surgery plus intraperitoneal chemotherapy |
| Q51916441 | Multimodality treatment of peritoneal carcinomatosis from colorectal cancer: first results of a new German centre for peritoneal surface malignancies. |
| Q26769938 | Multimodality treatment strategies have changed prognosis of peritoneal metastases |
| Q64235559 | Oxaliplatin Treatment Alters Systemic Immune Responses |
| Q55198257 | Oxaliplatin-induced changes in microbiota, TLR4+ cells and enhanced HMGB1 expression in the murine colon. |
| Q36741463 | Pathological complete response following neoadjuvant radiotherapy and intraperitoneal perfusion chemotherapy for recurrent colon carcinoma: A case report and literature review |
| Q64055171 | Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study |
| Q79317783 | Peritoneal carcinomatosis of colorectal origin |
| Q90356540 | Pharmacologic Properties of the Carrier Solutions for Hyperthermic Intraperitoneal Chemotherapy: Comparative Analyses Between Water and Lipid Carrier Solutions in the Rat Model |
| Q92617940 | Pharmacological principles of intraperitoneal and bidirectional chemotherapy |
| Q33416659 | Population pharmacokinetics of peritoneal, plasma ultrafiltrated and protein-bound oxaliplatin concentrations in patients with disseminated peritoneal cancer after intraperitoneal hyperthermic chemoperfusion of oxaliplatin following cytoreductive su |
| Q37145798 | Surgical cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis arising from the appendix. |
| Q60948065 | Systematic Review of Variations in Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Metastasis from Colorectal Cancer |
| Q40004701 | The long-term impact of hyperthermic intraperitoneal chemotherapy on survivors treated for peritoneal carcinomatosis: a cross-sectional study. |
| Q81488858 | [Rationale for oncological surgery in multimodal cancer treatments] |
| Q81568741 | [Scoring systems for clinical staging of peritoneal carcinomatosis. A critical analysis] |
Search more.